A study conducted in collaboration with the renowned Kildangan/Godolphin stud farm in Ireland has demonstrated the significant potential of bActivate, a novel product designed to improve fertility in mares, specifically addressing challenges commonly faced by thoroughbred breeding programs.
The study evaluated the effectiveness of bActivate in enhancing pregnancy rates among a group of nineteen gallop/thoroughbred mares. The results were truly exceptional. An impressive 89% (16 out of 19) of the mares treated with bActivate successfully became pregnant. Furthermore, all 14 mares who conceived went on to deliver healthy and live foals.
“These findings are very encouraging,” stated Vet Morten Pedersen lead researcher on the study. “Traditionally, low fertility rates can be a major obstacle in thoroughbred breeding programs. bActivate offers a promising solution by helping to identify and address hidden bacterial infections that might otherwise hinder pregnancy.”exclamation
[Quote from Kildangan/Godolphin representative about the study’s impact and potential benefits for the industry]
This study reinforces the potency and reliability of bActivate in significantly improving the reproductive success of breeding programs.exclamation
About Bojesen & Petersen Biotech ApS
Bojesen & Petersen Biotech ApS is a Danish biotechnology company dedicated to developing innovative solutions for improving equine reproductive health. bActivate is their flagship product, designed to address the challenge of dormant bacterial infections in mares, a significant cause of infertility.
Episode
